Newsroom

In the News

• Overview
• Press Releases
• Calendar of Events
• Publications
• In the News

Cellumen News Articles                    
View Press Releases »

• November 13, 2009
  Pittsburgh Business Times
  Pittsburgh Business Times editors highlight the advantages of Cellumen's rodent panel in predicting drug induced liver toxicity. Cellumen's in vitro Rat Hepatocyte Early Safety Assessment Panel is key to predicting earlier toxicity results and shrinking drug development costs.  This panel is poised to impact the Company's growth in 2010.
  
  
• May, 2009
  BioWorld Perspectives
  Donald P. Taylor, Senior Director of Marketing and Corporate Development at Cellumen, Inc., published an article in BioWorld entitled 'Early Safety Assessment Can Enhance Pipeline Value and Increase Profitability."  He defines how a biotech company can enhance the value of its clinical pipeline at the start of the hit-to-lead phase by more than $4 million when they apply early safety assessment procedures, and he describes how Cellumen's CellCiphr safety risk assessment solutions can enhance pipeline value and increase profitability.
  
  
• March 2, 2009
  Drug Discovery & Development
  In vitro toxicity testing has been used for many years, but the predictive power for either rodent, or human toxic liability has not been demonstrated, until recently. Cellumen's Cellular Systems Biology (CSB) approach can address the complexity of the system’s response to challenges, and early studies have demonstrated that a CSB profile shows predictive power not evident in simple cell-based assays.
  
  
• February 19, 2009
  Bio-IT World
  This comprehensive article first appeared in Bio-IT World’s Predictive Biomedicine newsletter. It highlights Cellumen's unique position to provide products and services to identify promising drug candidates and red-flag tox-causing compounds using Cellular Systems Biology. This Cellular Systems Biology approach sets Cellumen apart from all other biotech companies using high content screening in cell-based assays. The article also discusses Cellumen's Cardiac Tox Panel, HepG2 Panel and their future plans to use tissue microarrays as predictive tools for human toxicity.
  
  
• October 3, 2008
  BioCentury
  BioCentury Editors announce Cellumen's partnership with the Alzheimer’s Drug Discovery Foundation to create a celluar model of Alzheimer's disease (AD). Cellumen will use its Cellular Systems Biology (CSB) technology to develop a panel of assays and biosensors to determine target and pathway activity in AD.
  
  
• October 3, 2008
  Cell-Based Assay News
  Cell-Based Assay News' Charlotte LoBuono profiles Cellumen and its alliance with the Alzheimer's Drug Discovery Foundation to create a cellular model of Alzheimer's disease. Cellumen's Lansing Taylor explains, "This is part of our strategy of seeing the increased linkage between drug discovery, especially with more sophisticated celluar models of disease, and discovery toxicology that is applied very early on in the development process."
  
  
• October 2008
  Research and Markets
  Research and Markets spotlights a new report on early-stage toxicity prediction published by Decision Resources, Inc., and features Cellumen. Cellumen is a cellular systems biology company that supports drug discovery and development.
  
  
• October 2008
  Start-Up Magazine
  Deborah Erickson of Start-Up magazine interviews Cellumen’s D. Lansing Taylor in a profile about the company’s efforts in predictive toxicology. Cellumen is trying to help pharmaceutical clients distinguish toxic compounds from safe compounds through the use of cell-based assays. Taylor says, “We want to set the standard in the industry and become the preferred partner for outsourced discovery toxicology services and collaborative development.”
  
  
• September 11, 2008
  Bio-IT World
  Bio-IT World editors report on Cellumen's announcement to develop toxicology panels for Mitsubishi Tanabe. As part of this agreement, Cellumen will develop panels of biomarkers that identify toxicity early in the drug development process.
  
  
• August 27, 2008
  PA BIO Watch
  PA BIO Watch editors announce Cellumen's collaboration with Mitsubishi Tanabe Pharma Corporation. "By working together to develop biomarker panels," says D. Lansing Taylor, "we hope to identify toxic liabilities much earlier in the drug development process."
  
  
• August 25, 2008
  BioCentury
  BioCentury editors highlight Cellumen's collaboration with Mitsubishi Tanabe Pharma. Cellumen will be using its CellCiphr technology to develop biomarkers for MTPC's preclinical compounds.
  
  
• August 22, 2008
  Cell-Based Assay News
  Cell-Based Assay News' Charlotte LoBuono highlights Cellumen's collaboration with Mitsubishi Tanabe Pharma Corporation. Cellumen's Lansing Taylor describes the company's CellCiphr product line. "We started with existing panels, and are building a range of new ones."
  
  
• July 7, 2008
  Cell-Based Assay News

  Cell-Based Assay News’ Charlotte LoBuono reports on Cellumen’s decision to collaborate with the National Center for Toxicological Research to profile blinded samples of compounds. Donald Taylor says that the purpose of the project “is to validate the CellCiphr panels around liver toxicity.”